Consejo Superior De Investigaciones Cientificas

Vivia Biotech S.l.

Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud (fimabis)

FundaciÓ Institut Mar Dtnvestigacions MÈdioues

Servicio Andaluz De Salud

Universidad De Malaga

Euronutra, S.l.

Juan Manuel Decara Del Olmo

Fernando Rodríguez De Fonseca

Jesús Joglar Tamargo

Pedro Clapés Saborit

Bruno Almeida Cotrim

Montserrat Fito Colomer

Rafael De La Torre Fornell

Miguel Romero Cuevas

Francisco Javier Pavón Morón

Magí Ferre Albaladejo

Laura Orio Ortíz

Monica Alonso Scrignoli

Elena Baixeras Llano

Antonia Serrano Criado

María Isabel Covas Planells

Carlos Sanjuan Merino

Juan Antonio Navarro Galera

Dina Medina Vera

Fernando Rodriguez De Fonseca

Juan Suarez Perez

Cristina Rosell Del Valle

Antonio Jesús López Gambero

Mónica Alonso

Fernando Antonio RODRÍGUEZ De Fonseca

The invention relates to the use of fatty acid amides with phenylalkylamines and of a pharmaceutical composition comprising at least one of these compounds in the prevention and/or treatment of fatty liver or a pathological condition or disease caused by fatty liver, either alcoholic or non-alcoholic, and, in particular, for the prevention and/or treatment of the alcoholic steatohepatitis or non-alcoholic steatohepatitis (NASH).

Fatty acid amides for the prevention and/or treatment of steatohepatitis

The present invention relates to the use of a compound of formula (I): or a pharmaceutically acceptable solvate or salt thereof in the preparation of a medicinal product for the prevention and/or the treatment of a disease in which the GLP-1 receptor participates or mediates, such as eating disorders or diseases, for example, obesity, anorexia, lipid dysfunction, diabetes, hyperinsulinism and cardiovascular diseases or metabolic syndrome.

1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor

Growing community of inventors

Málaga, Spain

Juan Manuel Decara Del Olmo